HC Wainwright Initiates Monte Rosa Therapeutics With Buy, $25 Target
HC Wainwright & Co. initiated coverage of Monte Rosa Therapeutics' stock with a Buy rating and a $25 price target, implying a 109.6% upside from the previous close.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.